*Purpose: During the COVID-19 pandemic, telehealth utilization has allowed for the delivery of healthcare while protecting patients, caregivers, healthcare workers, and the community from exposure. We examined the effect of the COVID-19 pandemic on utilization of telehealth in the care of all solid organ transplant patients in all phases of transplant care at our center.

*Methods: All patients seen at Vanderbilt University Medical Center for solid organ transplant during any phase of care (referral, evaluation, waitlist, or post-transplantation) from July 1, 2019 through October 31, 2020 were included in this retrospective analysis. Patients seen from July 1, 2019 through February 29, 2020 were identified as a Pre-COVID-19 era cohort. Patients seen from March 1, 2020 through October 31, 2020 were the COVID-19 era cohort. Pretransplant phases of care included referral, evaluation and waitlist; those transplanted were considered posttransplant. Telehealth visits included telemedicine, defined as those conducted by face-to-face (F2F) videoconferencing, and telephone.

*Results: Total visit number for all solid organs (kidney, liver, heart, lung, and pancreas) were similar between eras (12585 vs. 13677) [Figure]. There was a significant increase in the use of telehealth in the COVID-19 era for all organ types with the pre-era ranging from 1.2-4.3% while post ranged from 22.4-45.6% [Table]. Telemedicine was not used during the pre-COVID-19 era and its use increased to 17.5-23.7% of all visits by organ type during the COVID-era.

*Conclusions: The COVID-19 pandemic has accelerated the use of telehealth in all phases and types of solid organ transplantation. The use of telemedicine although increased represents a minority of total visits and the increased use of telephone visits suggest barriers may remain to more widespread adoption of F2F technology that warrant further investigation.

« Back to 2021 American Transplant Congress